New Data Evaluating ABRAXANE In Early-Stage Breast Cancer And In Combination With Novel Investigational Agents To Be Presented At SABCS

News — By on December 11, 2008 at 8:00 am

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that multiple studies of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 31st Annual San Antonio Breast Cancer Symposium on December 10-14, 2008.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback